Clinical Trial: Evaluate the Safety and Efficacy of TRG-200 KIT in Patients With Refractory Overactive Bladder.

U.S., Feb. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07391878) titled 'Evaluate the Safety and Efficacy of TRG-200 KIT in Patients With Refractory Overactive Bladder.' on Dec. 22, 2025.

Brief Summary: This is an open-label, single-center pilot study designed to evaluate the safety, tolerability, and preliminary efficacy of TRG-200 KIT, an intravesical sustained-release oxybutynin formulation, in adult patients with refractory overactive bladder (OAB). The study includes an adaptive two-stage design with initial dose evaluation of two dose levels (150 mg and 300 mg oxybutynin) followed by expansion using the selected dose. TRG-200 KIT is administered via monthly intravesical instillation and aims to prov...